New combo therapy fights spreading prostate cancer
NCT ID NCT05171816
Summary
This large, late-stage study is testing whether adding a drug called olaparib to standard therapy (abiraterone) works better for men with advanced prostate cancer that has spread and is no longer controlled by hormone therapy alone. The goal is to see if the combination can delay cancer growth and improve survival. Participants are men who have not yet tried chemotherapy or newer hormone drugs for this advanced stage of their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100034, China
-
Research Site
Beijing, 100050, China
-
Research Site
Beijing, 100142, China
-
Research Site
Beijing, 100191, China
-
Research Site
Beijing, 100730, China
-
Research Site
Chongqing, 400038, China
-
Research Site
Guangzhou, 510180, China
-
Research Site
Guangzhou, 510515, China
-
Research Site
Guizhou, 550002, China
-
Research Site
Henan, 450008, China
-
Research Site
Hubei, 430030, China
-
Research Site
Hunan, 410008, China
-
Research Site
Hunan, 410013, China
-
Research Site
Jilin, 130012, China
-
Research Site
Jilin, 130021, China
-
Research Site
Liaoning, 110001, China
-
Research Site
Nanchang, 330006, China
-
Research Site
Nanjing, 2100008, China
-
Research Site
Ningbo, 315000, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Shanghai, 200040, China
-
Research Site
Sichuan, 610041, China
-
Research Site
Sichuan, 610072, China
-
Research Site
Xi'an, 710061, China
-
Research Site
Zhejiang, 310009, China
-
Research Site
Zhejiang, 310014, China
Conditions
Explore the condition pages connected to this study.